PharmaCorp Rx Inc.
PCRX.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 85.14% | 75.52% | 330.62% | 1,391.60% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 85.14% | 75.52% | 330.62% | 1,391.60% | -- |
| Cost of Revenue | 90.39% | 73.78% | 308.63% | 1,257.98% | -- |
| Gross Profit | 77.43% | 78.35% | 366.94% | 1,652.70% | -- |
| SG&A Expenses | 112.76% | 192.24% | 52.14% | 174.49% | 402.09% |
| Depreciation & Amortization | 94.03% | 79.24% | 190.29% | 731.10% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.72% | 106.89% | 136.47% | 421.46% | 1,470.07% |
| Operating Income | -123.21% | -278.39% | 55.71% | 45.94% | 194.81% |
| Income Before Tax | -66.23% | -188.32% | 56.60% | 62.10% | 267.98% |
| Income Tax Expenses | -108.12% | 418.30% | -2,383.33% | 57,200.00% | -- |
| Earnings from Continuing Operations | -48.48% | -222.37% | 58.55% | 35.79% | 217.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -56.98% | -184.11% | -1,123.08% | 200.00% | -- |
| Net Income | -53.86% | -220.58% | 56.62% | 36.24% | 212.25% |
| EBIT | -123.21% | -278.39% | 55.71% | 45.94% | 194.81% |
| EBITDA | -36.26% | -168.34% | 71.24% | 72.60% | -- |
| EPS Basic | -71.43% | -195.65% | 58.73% | 69.23% | 118.92% |
| Normalized Basic EPS | -84.62% | -169.23% | 53.85% | 81.63% | 128.26% |
| EPS Diluted | -69.23% | -195.65% | 58.73% | 69.23% | 117.57% |
| Normalized Diluted EPS | -83.33% | -169.23% | 53.85% | 81.63% | 126.09% |
| Average Basic Shares Outstanding | 48.41% | 26.48% | 3.66% | 110.80% | 478.43% |
| Average Diluted Shares Outstanding | 46.54% | 26.48% | 3.66% | 110.80% | 517.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |